Breast Cancer Liquid Biopsy Market Size & Growth Forecast 2026–2035, By Segments (Circulating Biomarkers, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Breast Cancer Liquid Biopsy Market size stood at USD 1.24 Billion in 2025 and is predicted to grow at a 8.5% CAGR from 2026 to 2035, exceeding USD 2.8 Billion by 2035. The industry revenue for 2026 is calculated at USD 1.33 billion.
Get more details on this report
Request Free Sample ReportBreast Cancer Liquid Biopsy Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for a 47.32% market share in 2025, supported by advanced oncology diagnostics, widespread molecular testing, and strong integration of liquid biopsy into clinical care pathways.
- Asia Pacific is expected to expand at a 9.61% CAGR, driven by broader access to oncology testing, growing adoption of minimally invasive diagnostics, and improving laboratory capabilities.
Segment Momentum
- Circulating Cell-free DNA (cfDNA) held a 56.28% share in 2025 because its minimally invasive approach supports repeated sampling, treatment monitoring, and efficient integration into routine clinical workflows.
- Early Detection/Screening is growing fastest as demand rises for less invasive testing that supports earlier clinical intervention, with repeatable and convenient liquid biopsy approaches expanding beyond treatment-stage decision-making.
Market Expansion Drivers
- Increasing breast cancer prevalence driving demand for rapid non-invasive diagnostic solutions.
- Growing transition from tissue biopsy to liquid biopsy improving cancer monitoring efficiency.
- Expanding precision oncology applications accelerating adoption of circulating tumor DNA testing technologies.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Leading players in the breast cancer liquid biopsy market include F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific Inc. (United States), NeoGenomics, Inc. (United States), Sysmex Corporation (Japan), Myriad Genetics, Inc. (United States), Menarini Silicon Biosystems S.p.A. (Italy), Epic Sciences, Inc. (United States), Biocept, Inc. (United States), Guardant Health, Inc. (United States).Regional and Segment Outlook
North AmericaMarket Growth Drivers and Industry Trends
Rising breast cancer incidence is pushing care pathways to handle larger diagnostic and follow-up volumes, which is reinforcing demand for faster, less burdensome testing approaches in the breast cancer liquid biopsy market. As clinicians seek tools that can be used repeatedly without the procedural delays, discomfort, and access limitations associated with tissue sampling, liquid biopsy becomes more attractive for early assessment, recurrence surveillance, and treatment response tracking. This trend supports market expansion by increasing the practical value of blood-based assays in routine oncology workflows, especially where repeat testing and quicker clinical decision-making are becoming more important.
Growing transition from tissue biopsy to liquid biopsy improving cancer monitoring efficiency
A gradual move away from relying solely on tissue biopsy is reshaping how breast cancer is monitored over time, driving market development in the breast cancer liquid biopsy market. Tissue biopsy often provides only a single-point view and can be difficult to repeat, while liquid biopsy fits more naturally into longitudinal care by allowing serial sampling during treatment and surveillance. That change is influencing market adoption because oncology teams can track tumor evolution with fewer procedural barriers, prompting healthcare providers and laboratories to integrate liquid biopsy platforms more directly into monitoring protocols and testing menus.
Expanding precision oncology applications accelerating adoption of circulating tumor DNA testing technologies
As treatment selection in breast cancer becomes more dependent on molecular profiling, circulating tumor DNA testing is gaining a clearer clinical role, contributing to market size growth in the breast cancer liquid biopsy market. Precision oncology requires timely insight into actionable mutations, resistance mechanisms, and evolving tumor biology, and ctDNA assays offer a practical way to generate that information when repeated molecular assessment is needed. This is increasing market penetration by encouraging oncologists, diagnostic developers, and laboratory networks to prioritize liquid biopsy technologies that align with targeted therapy decision-making and dynamic disease management.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing breast cancer prevalence driving demand for rapid non-invasive diagnostic solutions | 1.90% | High | North America, Europe | High | Near Term |
| Growing transition from tissue biopsy to liquid biopsy improving cancer monitoring efficiency | 1.70% | Moderate | Asia Pacific, North America | High | Mid Term |
| Expanding precision oncology applications accelerating adoption of circulating tumor DNA testing technologies | 1.40% | High | Europe, North America | Emerging | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America held the leading breast cancer liquid biopsy market position in 2025, accounting for a 47.32% share. Its leadership is backed by the region’s established oncology diagnostics infrastructure, broad availability of advanced molecular testing, and strong integration of liquid biopsy into clinical decision-making across cancer care pathways. In practice, this supports higher testing volumes through specialist cancer centers, reference laboratories, and hospital networks that can process samples quickly and use results to guide screening follow-up, treatment selection, and disease monitoring.
Asia Pacific is projected to expand at a 9.61% CAGR over the forecast period in the breast cancer liquid biopsy market, driven by accelerating adoption of modern cancer diagnostics across large patient populations and expanding access to oncology testing services. Growth is being fueled by the practical shift toward less invasive diagnostic approaches in markets where healthcare systems are increasing cancer detection efforts and improving laboratory capabilities. As more providers incorporate advanced blood-based testing into routine breast cancer assessment and monitoring, regional demand is rising through both urban hospital systems and developing diagnostic networks.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Clinical Validation FocusGermany is strengthening breast cancer liquid biopsy adoption through evidence-based clinical implementation and advanced laboratory capabilities. German healthcare providers are emphasizing diagnostic accuracy, standardized workflows, and molecular testing integration within oncology practice.
France 🇫🇷
Oncology Diagnostic InnovationFrance is promoting breast cancer liquid biopsy through precision oncology initiatives and broader use of molecular diagnostics. Clinical centers in France are incorporating liquid biopsy into patient management strategies to support treatment selection and disease monitoring.
Italy 🇮🇹
Personalized Cancer MonitoringItaly is expanding breast cancer liquid biopsy applications within personalized oncology care and advanced diagnostic services. Hospitals and diagnostic laboratories in Italy are adopting molecular testing solutions that enhance treatment monitoring while reducing reliance on invasive procedures.
Japan 🇯🇵
Early Detection IntegrationJapan is incorporating breast cancer liquid biopsy technologies into precision medicine initiatives that support earlier disease assessment and treatment monitoring. Clinical institutions in Japan continue evaluating validated assays that complement conventional diagnostic approaches.
South Korea 🇰🇷
Molecular Testing ExpansionSouth Korea is advancing breast cancer liquid biopsy through investments in molecular diagnostics and precision oncology services. Healthcare organizations are integrating liquid biopsy platforms into cancer management workflows while expanding access to innovative diagnostic technologies.
United States 🇺🇸
Precision Diagnostics AdoptionThe U.S. is expanding breast cancer liquid biopsy adoption through precision oncology programs and advanced molecular testing capabilities. Healthcare providers are integrating minimally invasive diagnostics into treatment monitoring and personalized care pathways supported by ongoing clinical validation.
Segment Leadership and Growth Trends
Breast Cancer Liquid Biopsy Market Share (%), Circulating Biomarkers, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportWithin the breast cancer liquid biopsy market, Circulating Cell-free DNA (cfDNA) accounted for a 56.28% share in 2025, making it the leading circulating biomarker segment. its position is maintained through the practical utility of cfDNA in capturing tumor-related genetic information through a minimally invasive blood-based approach that fits well into routine clinical workflows. In the breast cancer liquid biopsy market, this segment remains dominant because it supports repeated sampling and treatment monitoring in a way that is operationally more scalable for ongoing patient management.
Circulating Tumor Cells (CTCs) are emerging as the fastest-growing segment in the breast cancer liquid biopsy market as clinical interest increases around direct tumor cell analysis. Growth momentum is being backed by the need for richer biological insight beyond fragmented genetic material, particularly where understanding tumor behavior, progression, and treatment response can benefit from intact cellular evidence. Compared with alternative circulating biomarkers, CTCs are seeing wider adoption because they align with evolving demand for more comprehensive characterization of cancer dynamics through liquid biopsy.
Application Segment Analysis: Treatment Selection (Largest Segment) vs Early Detection/Screening (Fastest-Growing Segment)
Treatment Selection held a 54.08% share in 2025, positioning it as the largest application segment in the breast cancer liquid biopsy market. This leadership reflects the immediate clinical value of liquid biopsy in helping guide therapy decisions based on tumor-related molecular information obtained without invasive tissue procedures. The segment maintains its lead because treatment selection is closely tied to active care pathways, where timely biomarker insights can support more informed therapeutic choices and ongoing disease management.
Early Detection/Screening is the fastest-growing application in the breast cancer liquid biopsy market, influenced by rising interest in identifying malignancy earlier through less invasive testing approaches. Its momentum is backed by the practical appeal of expanding liquid biopsy use beyond treatment-stage decision-making into broader detection settings, where convenience and repeatability are especially relevant. Relative to other applications, Early Detection/Screening is gaining pace as the market increasingly focuses on earlier clinical intervention and more accessible testing pathways.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Circulating Biomarkers | Circulating Tumor Cells (CTCs), Circulating Cell-free DNA (cfDNA), Extracellular Vesicles (EVs), Others | Circulating Cell-free DNA (cfDNA) | Circulating Tumor Cells (CTCs) |
| Application | Early Detection/Screening, Diagnosis, Treatment Selection, Monitoring | Treatment Selection | Early Detection/Screening |
Competitive Landscape and Market Positioning
1. F. Hoffmann-La Roche Ltd. (Switzerland)
2. QIAGEN N.V. (Netherlands)
3. Thermo Fisher Scientific Inc. (United States)
4. NeoGenomics Inc. (United States)
5. Sysmex Corporation (Japan)
6. Myriad Genetics Inc. (United States)
7. Menarini Silicon Biosystems S.p.A. (Italy)
8. Epic Sciences Inc. (United States)
9. Biocept Inc. (United States)
10. Guardant Health Inc. (United States)
Technological progress in molecular diagnostics is significantly influencing the breast cancer liquid biopsy market. Industry players are concentrating on improving assay sensitivity, biomarker detection accuracy, and non-invasive testing capabilities to support earlier cancer detection and treatment monitoring. Ongoing research initiatives focused on expanding clinical applications and integrating genomic profiling tools are also strengthening the competitive environment and driving broader adoption of precision oncology solutions.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Illumina Inc. | Aug-24 | Illumina expanded its oncology portfolio by introducing high-throughput sequencing compatibility for the TruSight Oncology 500 ctDNA v2 assay. This update enhances the scalability of noninvasive genomic profiling, providing researchers with a more efficient tool for detecting circulating tumor DNA (ctDNA) variants essential for breast cancer research and therapeutic monitoring. |
| Twist Bioscience | Feb-24 | Twist Bioscience launched a specialized cfDNA library preparation kit designed to optimize liquid biopsy workflows. The kit improves the sensitivity and accuracy of variant detection from degraded or low-input cell-free DNA samples, facilitating more robust analytical performance for researchers developing diagnostic assays for early cancer detection and minimal residual disease monitoring. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Breast Cancer Liquid Biopsy Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Breast Cancer Liquid Biopsy Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchWhat is the current size of the breast cancer liquid biopsy market?
What are the growth projections for the breast cancer liquid biopsy industry?
How is the shift toward non-invasive diagnostic pathways changing clinical demand in the breast cancer liquid biopsy market?
Why is circulating tumor DNA testing becoming central to precision oncology applications in breast cancer management?
Why does Circulating Cell-free DNA (cfDNA) lead the breast cancer liquid biopsy market?
Why is Early Detection/Screening the fastest-growing application in the breast cancer liquid biopsy market?
Why does North America dominate the breast cancer liquid biopsy market?
What is driving growth in the breast cancer liquid biopsy market across Asia Pacific?
Who are the leading players in the breast cancer liquid biopsy landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization